ITEMS IN AFP WITH KEYWORD:
As the proportion of persons in the United States older than 65 years increases, the prevalence of dementia will increase as well. Risk factors for dementia include age, family history of dementia, apolipoprotein E4 genotype, cardiovascular comorbidities, chronic anticholinergic use, and lower educa...
Alzheimer disease is the most common form of dementia, affecting more than one-third of Americans older than 85 years. It is characterized by progressive memory loss and cognitive decline. Amyloid plaque accumulation, neurofibrillary tau tangles, and depletion of acetylcholine are among the patholog...
Undoubtedly, there is an increasing need to clarify the modifiable risk factors for cognitive impairment. Because the prevalence of dementia doubles every five years, the global burden of dementia will increase significantly—an impact that warrants a more anticipatory approach to identifying modifia...
Mar 15, 2011 Issue
Donepezil to Manage Alzheimer Disease: New vs. Standard Dosing [AFP Journal Club]
Does donepezil benefit patients with Alzheimer disease, and is the new dosage superior to the standard dosage? This study showed benefit, but the data are misleading.
Frontotemporal dementia (FTD) is one of the most common forms of dementia in persons younger than 65 years. Variants include behavioral variant FTD, semantic dementia, and progressive nonfluent aphasia. Behavioral and language manifestations are core features of FTD, and patients have relatively pre...
Nov 1, 2010 Issue
AAN Updates Guidelines on Evaluating Driving Risk in Patients with Dementia [Practice Guidelines]
Quality Standards Subcommittee of the American Academy of Neurology (AAN) updated guidelines for the evaluation and management of driving risk in persons with dementia. The new evidence-based guidelines offer characteristics that can help to identify persons that are at risk of unsafe driving.
Mar 15, 2009 Issue
Brief Screening Instruments for Dementia in Primary Care [Point-of-Care Guides]
In addition to identifying patients who may benefit from pharmacotherapy, early detection of dementia helps families anticipate the patient’s needs and helps physicians identify those in need of additional support.
Apr 15, 2008 Issue
AAFP and ACP Release Guideline on Dementia Treatment [Practice Guidelines]
A guideline created by the American Academy of Family Physicians (AAFP) and the American College of Physicians (ACP) reviews the data on the effects of pharmacologic treatment of dementia for improving cognition, global function, behavior/mood, and quality of life (QOL)/activities of daily living (ADL).
Cholinesterase inhibitors produce a small benefit on several cognitive and noncognitive function scales. Although data for patients with severe dementia are sparse, there is no evidence to suggest a difference in effectiveness among patients with mild, moderate, or severe dementia. Compared with pla...
Aug 1, 2006 Issue
Are Atypical Antipsychotics Safe in Patients with Alzheimer's Disease? [Cochrane for Clinicians]
Although the atypical antipsychotic medications risperidone (Risperdal) and olanzapine (Zyprexa) are modestly efficacious in reducing aggression, routine use is not justified. Both drugs are associated with serious adverse cerebrovascular events and extrapyramidal symptoms. Use of atypical antipsych...